Updated treatment of castration-resistant prostate cancer
XU Song
Abstract：Most prostate cancer cases ultimately relapse after a period of initial response to castration therapy and progress to intractable castration-resistant prostate cancer (CRPC).Hardly any therapeutic options currently used can improve the 2-to 3-year survival of the patient.Recently,some new drugs for the treatment of CRPC through various action mechanisms have been approved,and others are in the advanced stage of clinical trial.This review provides an overview of these new therapeutic agents.
Keywords：prostate cancercastrationtreatment
Publication Date：2014-11-16
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)